Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.35 |
| ▸ | CETP | P11597 | 5/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698156 | 0.93 | PDE4B (0.34) | PDE4BCETPFFAR1ACSS2SCN9A | |
| SCHEMBL23958797 | 0.84 | CFTR (0.36) | PDE4BACSS2ROCK2ROCK1P2RX7 | |
| SCHEMBL23958810 | 0.81 | CFTR (0.34) | PDE4BP2RX7HCRTR1HCRTR2 | |
| SCHEMBL25698171 | 0.80 | PDE4B (0.31) | PDE4BACSS2 | |
| SCHEMBL23958692 | 0.78 | CTSA (0.36) | ROCK2ROCK1 | |
| SCHEMBL23958652 | 0.74 | LMNA (0.33) | FFAR1ACSS2ROCK2ROCK1 | |
| SCHEMBL23958776 | 0.74 | LMNA (0.36) | PDE4BFFAR1ROCK2ROCK1P2RX7 | |
| SCHEMBL23195973 | 0.74 | BACE1 (0.33) | PDE4BP2RX7 | |
| SCHEMBL25697249 | 0.74 | CETP (0.34) | CETPROCK2ROCK1 | |
| SCHEMBL23958874 | 0.73 | CTSA (0.35) | PDE4BFFAR1ACSS2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | PDE4B 2848/4885CETP 4310/4885FFAR1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.